News

Pulmatrix was granted an important patent from the European Union (EU) for its proprietary iSPERSE technology, a platform for inhaled drug delivery based on unique properties developed for the treatment of lung diseases such as chronic obstructive pulmonary disease (COPD). “This new patent shows our continued ability to obtain patents that protect…

AstraZeneca and Circassia are partnering to develop and commercialize two inhaled respiratory treatments for chronic obstructive pulmonary disease (COPD) in the United States, Tudorza (aclidinium bromide) and Duaklir (aclidinium bromide). Tudorza was approved by the U.S. Food and Drug Administration (FDA) in 2012, and its marketing began that…

Metered-dose inhalers are a common device among patients with lung diseases, including chronic obstructive pulmonary disease (COPD), but users may be doing it wrong and limiting the medication’s effectiveness by getting only half the medication they need, according to two studies from Rice University. One study, “Factors Determining In…

Using Monaghan Medical’s Aerobika device as part of a treatment regimen may help reduce emergency room visits, hospital re-admissions and related costs, as well as the recurrence of exacerbations in patients with chronic obstructive pulmonary disease (COPD). The study reporting these findings, “A Real-World Study of 30-Day Exacerbation…

Chronic inflammation of the sinus cavities is more common among patients with chronic obstructive pulmonary disease (COPD) who also have bronchiectasis, underscoring the impact of chronic inflammation of the upper airways in more severe disease phases. The study, “Chronic rhinosinusitis is associated with higher prevalence and severity…

Smokers and ex-smokers may significantly reduce their risk of developing chronic obstructive pulmonary disease (COPD) by eating  more fruit and vegetables, according to new research. The study, which only included men, found that each additional serving of fruit or vegetables reduced their risk by 4 to 8 percent. But the…

International Biophysics Corporation announced a revenue growth of 34% in 2016 due to a 53% increase in unit sales of the AffloVest and other surgical product lines in the United States. AffloVest is a lung clearance therapy for patients with respiratory diseases such as chronic obstructive pulmonary disease (COPD). “As we enter our…

Bronchiectasis is increasingly recognized in patients with chronic obstructive pulmonary disease (COPD) who have worsening symptoms, including exacerbations and higher risk for pneumonia. Researchers presented their study, “Bronchiectasis in COPD: An Irrelevant Imaging Finding or a Clinically Important Phenotype?”  at the 2016 CHEST Annual Meeting in Los…

Boehringer Ingelheim is partnering with Weill Cornell Medicine to discover new treatment approaches to potentially halt or reverse the progression of chronic obstructive pulmonary disease (COPD). The three-year cooperative agreement will combine the research of Weill Cornell Medicine’s Department of Genetic Medicine in novel therapeutic concepts for airway repair…

Blocking a molecule that is a risk factor for chronic obstructive pulmonary disease (COPD) could be a path toward treating the disease, according to a study. Researchers demonstrated that blocking a factor known as RAGE (receptor for advanced glycan end products) prevented inflammatory signaling and reduced airway damage in mice. The…